Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[DNA damage and anticancer effect].

R Kanamaru1, C Ishioka, Y Konishi

  • 1Clinical Cancer Chemotherapy, Tohoku University.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 1, 1990
PubMed
Summary

Cancer chemotherapy and antibacterial chemotherapy target DNA. Anticancer drugs like quinocarmycin, YM534, and MCNU showed antitumor action linked to DNA strand scission.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13AR.

ESMO open·2025
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer.

ESMO open·2024
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer.

ESMO open·2023
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Functional differences among BRCA1 missense mutations in the control of centrosome duplication.

Oncogene·2011

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Cancer chemotherapy shares mechanisms with antibacterial chemotherapy, primarily targeting DNA and its precursors.
  • DNA damage or metabolic abnormalities are common outcomes of anticancer drug activity in cancer cells.
  • Alkylating agents and anticancer antibiotics, along with newer drugs, target DNA strands or DNA synthesis.

Purpose:

  • To investigate the antitumor mechanisms of quinocarmycin (KT 6149), YM534, and MCNU.
  • To determine the relationship between the antitumor effects of these agents and their impact on DNA strands.
  • To elucidate the DNA-damaging properties of these specific anticancer drugs.

Summary:

  • Quinocarmycin (a mitomycin C derivative), YM534 (with thrombocyte agglutination activity), and MCNU (a nitrosourea) were studied for their anticancer mechanisms.
  • All tested agents demonstrated a correlation between their antitumor efficacy and the induction of single-strand breaks in DNA.
  • The study highlights DNA strand scission as a key mechanism of action for these anticancer agents.

Impact:

  • Establishes a direct link between DNA single-strand scission and the antitumor activity of quinocarmycin, YM534, and MCNU.
  • Provides insights into the molecular mechanisms of action for novel and existing anticancer drugs.
  • Contributes to the understanding of DNA-targeted cancer chemotherapy and drug development.

Related Experiment Videos